{"id":"https://openalex.org/W2954088728","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps7062","title":"CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia.","display_name":"CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia.","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2954088728","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps7062","mag":"2954088728"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.tps7062","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps7062","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps7062","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000750846","display_name":"Farhad Ravandi","orcid":"https://orcid.org/0000-0002-7621-377X","observed_orcids":["https://orcid.org/0000-0002-7621-377X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farhad Ravandi","raw_affiliation_strings":["The University of Texas, MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas, MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032665185","display_name":"Stephen Anthony Strickland","orcid":"https://orcid.org/0000-0002-6861-2041","observed_orcids":["https://orcid.org/0000-0002-6861-2041"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Anthony Strickland","raw_affiliation_strings":["Vanderbilt University Ingram Cancer Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Ingram Cancer Center, Nashville, TN;","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006999192","display_name":"Scott R. Solomon","orcid":"https://orcid.org/0000-0003-2061-8126","observed_orcids":["https://orcid.org/0000-0003-2061-8126"]},"institutions":[{"id":"https://openalex.org/I101890099","display_name":"Northside Hospital","ror":"https://ror.org/01g63ab19","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I101890099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott R. Solomon","raw_affiliation_strings":["The Leukemia Program at Northside Hospital Cancer Center Institute, Atlanta, GA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Leukemia Program at Northside Hospital Cancer Center Institute, Atlanta, GA;","institution_ids":["https://openalex.org/I101890099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086233229","display_name":"Aziz Nazha","orcid":"https://orcid.org/0000-0002-6695-7994","observed_orcids":["https://orcid.org/0000-0002-6695-7994"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aziz Nazha","raw_affiliation_strings":["Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013626352","display_name":"Roland B. Walter","orcid":"https://orcid.org/0000-0002-9268-3341","observed_orcids":["https://orcid.org/0000-0002-9268-3341"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roland B. Walter","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060321711","display_name":"Ilaria Valimberti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Ilaria Valimberti","raw_affiliation_strings":["Menarini Ricerche S.p.A., Florence, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Menarini Ricerche S.p.A., Florence, Italy;","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037389511","display_name":"Alessia Tagliavini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessia Tagliavini","raw_affiliation_strings":["Menarini Ricerche S.p.A., Florence, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Menarini Ricerche S.p.A., Florence, Italy;","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063483784","display_name":"Caterina Fiesoli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Caterina Fiesoli","raw_affiliation_strings":["Menarini Ricerche S.p.A., Florence, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Menarini Ricerche S.p.A., Florence, Italy;","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085370027","display_name":"Monica Binaschi","orcid":"https://orcid.org/0000-0002-3155-3164","observed_orcids":["https://orcid.org/0000-0002-3155-3164"]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Monica Binaschi","raw_affiliation_strings":["Menarini Ricerche SpA, Pomezia, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Menarini Ricerche SpA, Pomezia, Italy;","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025138388","display_name":"Krzysztof D. Brz\u00f3zka","orcid":"https://orcid.org/0000-0001-7563-6482","observed_orcids":["https://orcid.org/0000-0001-7563-6482"]},"institutions":[{"id":"https://openalex.org/I4405262242","display_name":"Selvita (Poland)","ror":"https://ror.org/028493376","country_code":"PL","type":"other","lineage":["https://openalex.org/I4405262242"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Krzysztof Brzozka","raw_affiliation_strings":["Selvita S.A., Krakow, Poland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Selvita S.A., Krakow, Poland;","institution_ids":["https://openalex.org/I4405262242"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112017931","display_name":"Simone Baldini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Simone Baldini","raw_affiliation_strings":["Menarini Ricerche, Firenze, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Menarini Ricerche, Firenze, Italy;","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011107920","display_name":"Steffen Heeger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405262242","display_name":"Selvita (Poland)","ror":"https://ror.org/028493376","country_code":"PL","type":"other","lineage":["https://openalex.org/I4405262242"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Steffen Heeger","raw_affiliation_strings":["Selvita S.A., Krakow, Poland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Selvita S.A., Krakow, Poland;","institution_ids":["https://openalex.org/I4405262242"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038079010","display_name":"Andrea Ugo Enrico Pellacani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Andrea Ugo Pellacani","raw_affiliation_strings":["Menarini Ricerche SpA, Firenze, Italy;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Menarini Ricerche SpA, Firenze, Italy;","institution_ids":["https://openalex.org/I4210108499"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"TPS7062","last_page":"TPS7062"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12582","display_name":"Flavonoids in Medical Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pim-kinase-inhibitors","display_name":"PIM kinase inhibitors","score":0.8389999866485596},{"id":"https://openalex.org/keywords/flt3-inhibitors","display_name":"FLT3 inhibitors","score":0.9319999814033508},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9300000071525574},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.9330000281333923},{"id":"https://openalex.org/keywords/flt3-inhibitor-resistance","display_name":"FLT3 inhibitor resistance","score":0.843999981880188},{"id":"https://openalex.org/keywords/dual-kinase-inhibitors","display_name":"dual kinase inhibitors","score":0.8009999990463257},{"id":"https://openalex.org/keywords/oral-kinase-inhibitor","display_name":"oral kinase inhibitor","score":0.753000020980835},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.8230000138282776},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8740000128746033},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.48399999737739563},{"id":"https://openalex.org/keywords/antileukemic-activity","display_name":"antileukemic activity","score":0.7440000176429749},{"id":"https://openalex.org/keywords/relapsed-refractory-aml","display_name":"relapsed/refractory AML","score":0.6830000281333923},{"id":"https://openalex.org/keywords/quizartinib","display_name":"quizartinib","score":0.7459999918937683},{"id":"https://openalex.org/keywords/azd1208","display_name":"AZD1208","score":0.972000002861023}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9121671915054321},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5800110697746277},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.532331109046936},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48979830741882324},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.44679901003837585},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.44399121403694153},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.44156578183174133},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.41778242588043213},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.41092872619628906},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38953518867492676},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.tps7062","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps7062","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps7062","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9789000153541565}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8100000023841858}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2035482751","https://openalex.org/W2375707865","https://openalex.org/W3030779772","https://openalex.org/W4236316986","https://openalex.org/W1570595782","https://openalex.org/W2990397977","https://openalex.org/W2781637722","https://openalex.org/W2364732766","https://openalex.org/W1980883331","https://openalex.org/W2012639655"],"abstract_inverted_index":{"TPS7062":[0],"Background:":[1],"FLT3-ITD":[2,20],"is":[3,31,106,134,214,247,268],"one":[4],"of":[5,46,76,87,122,189,200,226,286],"the":[6,162,169,179,184,263,269,278],"most":[7],"common":[8],"genetic":[9],"lesions":[10],"in":[11,23,33,78,109,124,141,258,262,283],"acute":[12],"myeloid":[13],"leukemia":[14],"(AML).":[15],"PIM":[16,28,47,97,212],"kinases":[17,48],"are":[18,197],"oncogenic":[19],"targets":[21],"expressed":[22],"AML":[24,37,63,79,84,125,284],"cells":[25,60],"and":[26,54,82,118,187,241,253,260],"increased":[27],"kinase":[29],"expression":[30],"found":[32],"relapse":[34],"samples":[35],"from":[36],"patients":[38,126,196],"treated":[39],"with":[40,93,145,211,277],"FLT3":[41,52,88,95,207,287,294],"inhibitors.":[42],"In":[43,168,192],"addition,":[44],"inhibition":[45,57],"restores":[49],"sensitivity":[50],"to":[51,91,160,181,206,232,280,292],"inhibitors":[53,98,213],"dual":[55,69,274],"FLT3/PIM":[56],"eradicates":[58],"FLT3-ITD+":[59],"including":[61],"primary":[62,83],"cells.":[64],"SEL24/MEN1703,":[65],"a":[66,72,107,142,157,221,273,290],"potent":[67],"PIM/FLT3":[68,275],"inhibitor,":[70],"demonstrates":[71],"significantly":[73],"broader":[74],"spectrum":[75],"activity":[77],"cell":[80],"lines":[81],"blasts,":[85],"irrespective":[86],"status,":[89],"compared":[90],"monotherapy":[92],"either":[94],"or":[96,102,151],"such":[99],"as":[100],"quizartinib":[101],"AZD1208.":[103],"Methods:":[104],"CLI24-001":[105],"First":[108],"Human,":[110],"open":[111],"label,":[112],"non-randomized,":[113],"multi-center,":[114],"Phase":[115],"I/II":[116],"dose-escalation":[117],"cohort":[119,264],"expansion":[120,265],"study":[121,194,246],"SEL24/MEN1703":[123,133,177],"(excluding":[127],"APL)":[128],"not":[129,215],"suitable":[130],"for":[131,138],"chemotherapy.":[132],"given":[135],"orally,":[136],"QD,":[137],"14":[139],"days":[140],"21-day":[143],"cycle":[144],"cycles":[146],"repeated":[147],"until":[148],"disease":[149],"progression":[150],"unacceptable":[152],"toxicity.":[153],"Dose":[154],"escalation":[155],"follows":[156],"3+3":[158],"design":[159],"identify":[161],"recommended":[163],"phase":[164,170],"2":[165,171],"dose":[166],"(RP2D).":[167],"part/cohort":[172],"expansion,":[173],"subjects":[174],"will":[175,254],"receive":[176],"at":[178,249],"RP2D,":[180],"further":[182],"investigate":[183],"safety":[185],"profile":[186],"signs":[188],"antileukemic":[190],"activity.":[191],"both":[193,257],"parts,":[195],"eligible":[198],"regardless":[199,285],"mutational":[201],"status":[202,288],"and/or":[203],"prior":[204,209],"exposure":[205],"inhibitors;":[208],"treatment":[210],"allowed.":[216],"Main":[217],"inclusion":[218],"criteria":[219],"comprise":[220],"white":[222],"blood":[223],"count":[224],"(WBC)":[225],"\u226430":[227],"x":[228],"109/L":[229],"(hydroxyurea/leukoapheresis":[230],"permitted":[231],"lower":[233],"WBC).":[234],"Key":[235],"secondary":[236],"objectives":[237],"include":[238],"pharmacokinetics":[239],"(PK)":[240],"single":[242],"agent":[243],"efficacy.":[244],"The":[245],"enrolling":[248],"5":[250],"US":[251,259],"sites":[252],"be":[255,281],"extended,":[256],"EU,":[261],"part.":[266],"This":[267],"first":[270],"trial":[271,305],"testing":[272],"inhibitor":[276,295],"potential":[279,291],"active":[282],"andwith":[289],"overcome":[293],"resistance.":[296],"(Sci":[297],"Adv.":[298],"2015;1:e1500221;":[299],"Oncotarget.":[300],"2018":[301],"Mar":[302],"30;9(24):16917-16931)":[303],"Clinical":[304],"information:":[306],"NCT03008187.":[307]},"counts_by_year":[],"updated_date":"2026-09-22T17:25:34.749102","created_date":"2025-10-10T00:00:00"}